Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q‐switched fractional 1064‐nm Nd:YAG laser: A blinded RCT and follow‐up. (1st November 2021)

• Record Type: Journal Article
• Authors: Behrangi, Elham; Shemshadi, Mahsa; Ghassemi, Mohammadreza; Goodarzi, Azadeh; Dilmaghani, Sara
• Is Part Of: Journal of cosmetic dermatology. Volume 21:Number 1(2022)
• Page Start: 279
• Page End: 289
• Publication Date: 2021-11-01
• Subjects: laser -- melasma -- microinjection -- Q‐switched -- RCT; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.14496
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: Melasma is a common hyperpigmentation disorder. This study aimed to compare the efficacy of Nd‐Yag fractional 1064 plus microinjection of tranexamic acid versus Nd‐Yag fractional 1064 plus oral tranexamic acid in patients with melasma. Materials and methods: This is a prospective, randomized study with a sample size of 40 patients, 20 in each treatment arm, which was done six times with 2‐week intervals. Twenty patients were administered localized microinjections (4 mg/ml) of tranexamic acid and Q‐switched 1064 laser every 2 weeks in one arm, while in the other arm, 20 were given oral tranexamic acid 250 mg three times a day and Q‐switched 1064 laser every 2 weeks per visit. Results: Twenty‐one patients with mean SD 40.52+‐4.95 y/o were treated with oral tranexamic acid, and 20 patients with 43.3+‐5.87 y/o treated with microinjection of tranexamic acid were analyzed. There was no statistically significant difference between the two groups in terms of demographic and clinical characteristics at the baseline ( p > 0.05). The patients MASI score and ∆E decrease over the study period in both treatments significantly ( p < 0.001). However, patient's MASI score ( p = 0.99) and ∆E ( p = 0.53) did not differ significant between the two group over the time. Satisfaction ( p = 0.41) and complication during the study period ( p = 0.09) were not significantly different between the two group. Conclusion: The combination treatment method can be a viable option for Middle Eastern patients having melasma disorder, and tranexamic acid appears to be an effective and safe treatment for melasma, irrespective of its route of administration. Tranexamic acid can increase the permeability locally by non‐invasive methods such as microneedling which is less painful than microinjection and can also increase patient satisfaction. Although the oral method is more tolerable for the patient, it may have systemic side effects, and its combination with Q‐switch laser increases its effect regardless of the type of prescription. Therefore, it is recommended to use of this drug topically (cream or lotion) by non‐invasive methods like microneedling to reduce pain and laser treatment in future studies.